NIEUWE ANALYSES VAN HET FASE 2 EQUATOR-KLINISCHE PROGRAMMA ONDERSTEUNEN DE DUURZAME WERKZAAMHEID VAN FILGOTINIB BIJ PSORIATISCHE ARTRITIS

NEXT STORY
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PREV STORY
Medical and Lab Refrigerator Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product Type ; End User ; and Geography
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea

REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. ...

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Announces R&D Day on June 26 to Review Endocrinology Rare Disease Pipeline and Introduce Oncology Programs

author_avatar
NASDAQ Market News

Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies

author_avatar
NASDAQ Market News